Eli Lilly wins China approval for first oral GLP-1 weight-loss drug, beating Novo Nordisk

China's NMPA approved Eli Lilly's orforglipron (Foundayo) as the first oral GLP-1 treatment for obesity, marking a competitive win over Novo Nordisk in the world's second-largest weight-loss market. The approval expands Lilly's access to a massive patient pool, intensifying the global GLP-1 race. Regulatory speed and market size suggest significant commercial upside, though pricing and reimbursement details remain unclear.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works